Margaret Horn
SANGAMO THERAPEUTICSAbout Margaret A. Horn
Margaret A. Horn, age 62, is an independent director at Sangamo Therapeutics (SGMO) since December 2022. She is Chief Operating Officer of Revolution Medicines (public) since October 2018 and previously served as its Executive Vice President & General Counsel; earlier roles include senior legal and corporate development leadership at Kosan Biosciences and Genencor International. She holds a B.S. in Pharmacy (Philadelphia College of Pharmacy and Science), a J.D. (Villanova University), and an executive M.B.A. (Pennsylvania State University) . The Board has determined she is independent under Nasdaq rules .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Revolution Medicines, Inc. | Executive Vice President & General Counsel | Dec 2014 – Oct 2018 | Led strategic and financing transactions (R&D collaborations, licenses, M&A, equity financings) |
| Kosan Biosciences, Inc. | Senior Vice President, Legal and Corporate Development | Not disclosed in proxy | Strategic transactions leadership |
| Genencor International, Inc. | Senior Vice President, Legal | Not disclosed in proxy | Legal leadership |
External Roles
| Organization | Role | Tenure | Notes |
|---|---|---|---|
| Revolution Medicines, Inc. (public) | Chief Operating Officer | Oct 2018 – Present | Leads corporate development, legal, information sciences, facilities |
Board Governance
- Committee assignments: Member, Nominating & Corporate Governance Committee (Chair: H. Stewart Parker; other member: John H. Markels) .
- Independence: Independent director; Board independence determined for all directors except the CEO .
- Attendance: In 2024, the Board held 24 meetings; each director attended ≥75% of combined Board and committee meetings. Eight of nine directors attended the 2024 annual meeting (virtual) .
- Leadership: Independent Chair of the Board (H. Stewart Parker); independent directors hold regular executive sessions without management .
Fixed Compensation
| Component | 2024 Amount | Notes |
|---|---|---|
| Fees Earned or Paid in Cash | $56,875 | Quarterly-paid retainers, prorated as applicable |
| Total Cash Retainer Structure (reference) | Board: $40,000; Audit Chair: $20,000; Comp Chair: $15,000; Nominating Chair: $10,000; Audit member: $10,000; Comp member: $7,500; Nominating member: $5,000 | Board waived meeting fees beyond 10 meetings in 2024 |
Performance Compensation
| Grant Type | Grant Date | Shares/Units | Exercise Price | Fair Value (Grant) | Vesting | Change-in-Control |
|---|---|---|---|---|---|---|
| Stock Option (NSO) | Jun 4, 2024 | 50,000 | $0.57/share | $19,885 | 12 equal monthly installments after grant | Immediate full vesting for director awards upon change in control or hostile takeover |
| RSU | Jun 4, 2024 | 25,000 | N/A | $14,190 | Fully vests on 1st anniversary of grant | Immediate full vesting for director awards upon change in control or hostile takeover |
- Clawback: Awards under the equity plan are subject to recoupment per the Company’s clawback policy and applicable law .
- Performance metrics: Director automatic grants are time-based; no company performance conditions are disclosed for director equity .
Other Directorships & Interlocks
| Company | Capacity | Interlock/Transaction Disclosure |
|---|---|---|
| Revolution Medicines, Inc. | Executive (COO) | Proxy describes related-party transaction oversight process; specific transactions involving Ms. Horn are not identified in the provided sections |
- Related-party governance: Audit Committee must review and approve related-party transactions; considers independence impacts and economics .
Expertise & Qualifications
- Strategic transactions leadership across biotech (collaborations, commercialization agreements, licensing, M&A, equity financing) .
- Legal and corporate development expertise; operational leadership as COO of a public oncology biotech .
- Education: B.S. Pharmacy; J.D.; executive M.B.A. .
Equity Ownership
| Ownership Detail | Amount | Notes |
|---|---|---|
| Total Beneficial Ownership | 166,649 shares; <1% of outstanding | Calculated on 229,192,802 shares outstanding as of Apr 17, 2025 |
| Options exercisable within 60 days | 115,250 shares (109,000 vest within 60 days; 6,250 exercisable but unvested and subject to repurchase if exercised before vesting) | As of Apr 17, 2025 |
| RSUs vesting within 60 days | 25,000 shares | As of Apr 17, 2025 |
| Hedging/Pledging | Prohibited for directors under Insider Trading Policy (including hedging, derivatives, short-selling, holding in margin accounts, pledging) |
Governance Assessment
- Strengths: Independent status; service on Nominating & Corporate Governance Committee; Board-level attendance threshold met; independent Chair and regular executive sessions enhance oversight .
- Alignment: Director equity granted annually (options + RSUs) aligns director incentives with shareholder outcomes; awards subject to clawback policy and standard vesting schedules .
- Potential investor concerns (monitor): Automatic full acceleration of director equity upon change in control/hostile takeover may be viewed as anti-takeover and can weaken alignment around sale price negotiation . Director grants are time-based (no performance conditions), standard for directors but lacks explicit performance ties .
- Conflicts: Ms. Horn is an operating executive at Revolution Medicines (public); no related-party transactions with SGMO are identified in the proxy sections reviewed, and the Audit Committee oversees any such matters to protect independence .